Advanced prostate cancer treatments continue to evolve with new treatments in the M0CRPC, such as daralutamide and apalutamide, precision treatments based on genetic testing including PARP inhibitors and PD1 immunotherapy. Genetic testing is helping to guide treatment and identify high risk familial genetic traits to help identify appropriate screening for family members. This presentation covers these topics and new breakthroughs.
Continuing Education Instructions and Disclosure Information:
Contact hours available until 10/18/22.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.
Faculty, Planners, and Speakers Conflict of Interest Disclosure:
Planning Committee Disclosures: Christina Hegan, MS, APRN, WHNP-BC Consultant for Urovant Sciences Spouse is a distributor for CBD rich hemp oil
There are no other Planning Committee disclosures to declare.
Speakers Conflict of Interest Disclosure: Leanne Schimke, MSN, NP, CRNP, CUNP Speakers Bureau for Bayer and Pfizer
There are no other speaker disclosures to declare.
Commercial Support and Sponsorship: No commercial support or sponsorship declared.
Accreditation Statement: Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
The SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is also a provider approved by the California Board of Registered Nursing, Provider Number CEP 5556. Accreditation and approved provider status of CE in nursing does not imply ANCC-COA approval or endorsement of any product, advertising, or educational content. SUNA urges all participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.
Learning Outcome: After completing this education activity, the learner will be able to discuss the reason for genetic testing in men with advanced prostate cancer, implications for their family and use of new prostate cancer medications that are more targeted for their prostate cancer, including PARP inhibitors and the possible side effects to monitor for with their use.